We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

SeraNovo and Carna Biosciences Enter Second License Agreement for Development of Oral Formulation of Kinase Inhibitor

Product News   May 26, 2020

 
SeraNovo and Carna Biosciences Enter Second License Agreement for Development of Oral Formulation of Kinase Inhibitor

Credit: Unsplash

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Avacta Announces Distribution Agreement With ABCAM plc

Product News

Avacta Group plc has announced that it has entered into a global distribution agreement with ABCAM plc to sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer® reagents.

READ MORE

Metrion Biosciences Closes £2.7m New Equity Financing

Product News

Metrion Biosciences Limited has announced that it has secured £2.7m in new equity financing, including £2.25m from lead investor Gresham House Ventures. The funding will be used to expand Metrion’s laboratories in Cambridge, UK, invest in specialist equipment, develop its cell line library, and add GLP cardiac safety services.

READ MORE

Investigating the Properties of Novel Polymer Nanogels

Product News

TESTA Analytical Solutions e.K reports how researchers have derived in-depth information about an exciting new generation of polymer nanogels.

READ MORE

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE